As anticipated, our results confirmed that quantitative relaxometry using SyMRI could differentiate IDH-mutant gliomas, leading to an increased sensitivity compared to the qualitative T2-FLAIR mismatch sign. The gene discussed is IDH2; the disease is central nervous system cancer.